BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Pfizer's (PFE) shares jump after FDA grants fast track status to two coronavirus vaccine candidates

Pfizer/BioNTech's Coronavirus Vaccine Gets FDA Fast Track Tag

Johnson & Johnson

Moderna

Novavax

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

BioNTech: Promising Early COVID-19 Data, But Still A Long Way To Go

BioCryst Pharmaceuticals

Biosig Technologies Inc

CytoDyn Inc.

Eiger BioPharmaceuticals

Gilead Sciences

Immunic Inc

Regeneron Pharmaceuticals

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

The companies expect to manufacture 100 million doses by the end of 2021.

Pfizer and BioNTech Get "Fast Track" Designation for 2 COVID-19 Vaccines

The FDA handed the German biotech some good news for two coronavirus vaccine candidates.

Why BioNTech Stock Is Soaring Today

BioNTech stock surged Monday after the drug maker's Pfizer-partnered coronavirus vaccines nabbed a speedier development and review designation.
The post Pfizer, BioNTech Pop After Coronavirus Vaccine Nabs Speedy Review appeared first on Investor's Business Daily.

Pfizer, BioNTech Pop After Coronavirus Vaccine Nabs Speedy Review

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) announced an update on their coronavirus vaccine program Monday that sent both stocks sharply higher.

Pfizer, BioNTech Coronavirus Vaccine Candidates Granted Fast Track Designation By FDA, Study On Track For July Start

Two experimental coronavirus vaccines by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer have received the U.S.

Pfizer, BioNTech's coronavirus vaccines get FDA's 'fast track' status

Shares of Pfizer Inc. PFE, +1.10% rallied 2.3% and of BioNTech SE BNTX, +7.24% jumped 5.3% in premarket trading Monday, after the companies said two of their vaccine candidates to protect against the virus that causes COVID-19 received Fast Track designation status from the Food and Drug Administration.

Pfizer, BioNTech stocks surge after COVID-19 vaccine candidates get Fast Track designation

Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020 Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates  Against SARS-CoV-2

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Livongo Health Inc

Here's why the stocks of digital health company Livongo Health and COVID-19 vaccine developer BioNTech look attractive.

2 Healthcare IPOs Getting a Tailwind From COVID-19 to Consider Buying

The companies' CEOs give different timelines on a potential submission.

Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

One of the world's leading coronavirus vaccine efforts reported promising progress.

Here's Why BioNTech Gained 34.8% in June

iShares Nasdaq Biotechnology ETF

Sanofi

COVID-19 has been the biggest driver of the stock market this year, whether it was the crash in March or recovery that has taken place since then.

5 Speculative COVID-19 Stocks That Could Still Surge

AstraZeneca

Shares of Moderna Inc (NASDAQ: MRNA), a frontrunner in the race for a coronavirus vaccine, tumbled Thursday afternoon after a STAT News report suggested there could be a delay in the initiation of a late-stage study.

Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More

Merck

Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years.

Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Implied Volatility Surging for BioNTech (BNTX) Stock Options

Investors are excited about the drug maker's experimental coronavirus vaccine.

Why Pfizer Stock Rose Today

Stocks moved higher to start the third quarter.

S&P 500 Jumps 0.5% After Pfizer Coronavirus Vaccine News

Patients developed antibodies to the coronavirus in the phase 1 clinical trial, but the vaccine also produced side effects.

Pfizer and BioNTech Post Positive Trial Data for Their COVID-19 Vaccine

Pfizer Inc. which is one of the five companies shortlisted by the U.S. government's Operation Warp Speed coronavirus vaccine program, reported positive preliminary data Wednesday.

Pfizer, BioNTech Report Promising Initial Data From Coronavirus Vaccine Study

Pfizer Inc. (NYSE: PFE) and BioNTech S.E. (NASDAQ: BNTX) advanced on Wednesday (in more ways than one) when they provided an update on their COVID-19 vaccine. These companies have been collaborating to produce a messenger RNA (mRNA) based vaccine for the past few months, and this work is yielding promising results.

Meet the New Frontrunners in the Race for a COVID-19 Vaccine

BioNTech's BNTX, +1.42% stock was halted and shares of Pfizer Inc. PFE, +4.15% gained 4.7% in trading on Wednesday morning after the companies said that all 24 participants in the Phase 1/2 clinical trial who received one of two lower doses of a COVID-19 vaccine candidate developed neutralizing antibodies.

News for BioNTech SE Stock (BNTX)